forecast

PCSK9 Should Outgrow GLP-1 Long Term

Because PCSK9 has an asymmetric benefit and risk profile, its long-run patient count and revenue should exceed GLP-1s, but adherence is harder since high LDL produces no felt symptoms.

forecastpending

Speaker

Alex

Evidence Quote

“this medicine should be far bigger in terms of the number of people that are on it”

Source

Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]— Invest Like the Best
Created: 11/14/2026, 4:24:39 AM

Your notes

Loading notes...